 |
|
|
| |
Long-Term Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Infection Is Safe and Well Tolerated and Associated with Durable Virologic Response with No Detectable Resistance: 8 Year Results from Two Phase 3 Trials
|
| |
| |
Reported by Jules Levin
APASL 2015 march 12-15, Istanbul, Turkey
S Gurel1, H Senturk2, P Marcellin4, US Akarca3, R Flisiak5, J Petersen6, N Tsai7, R Aguilar Schall8, JF Flaherty8, KM Kitrinos8, GM Subramanian8, JG McHutchison8, H Janssen9, M Buti10, and E Gane11
1Uludag Universitesi Tip Fakultesi, Bursa, Gorukle, Turkey; 2Bezmi Alem University, Istanbul, Turkey; 3Ege Universitesi Tip Fakultesi Hastanesi, Ismur, Turkey; 4Hopital Beaujon, Clichy, France; 5Medical University of Bialystok, Bialystok, Poland, 6Asklepios Klinik St. George, University of Hamburg, Hamburg, Germany, 7Queens Medical Center, University of Hawaii, Honolulu, HI, 8Gilead Sciences, Inc., Foster City, CA, 9University of Toronto, Toronto, Ontario, Canada, Hospital General 10Universitari Vall d'Hebron and Ciberehd, Barcelona, Spain, 11Auckland City Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
